Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Sponsor: LB Pharmaceuticals Inc.
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Official title: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
456
Start Date
2026-03
Completion Date
2027-10
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
LB-102 (50 mg tablet)
LB-102 oral tablet given for six weeks
LB-102 (100 mg tablet)
LB-102 oral tablet given for six weeks
Placebo
Placebo tablet given orally for six weeks